Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: The Dodgy Ticker who wrote (446)	12/24/2000 12:44:42 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

Bob: I don't know. The note in the last 10-K said that OSIP was electing not to renew the Solvay agreement, given their focus on oncology. Makes one think that their plate is full. note...... the Solvay project is, nonetheless, still listed as IND track. OSIP should toe the "forthright" line with respect to the GPCR projects. Goddard et al. have bounced around from project to project as though they were either ping pong balls or John Walker. Just ask Miljenko, it's his favorite topic. :-) I still feel that it's wise to fold it in with a hot-technology company that is pre-IPO. Some companies need an additional round of funding just before going public. They give away a nice chunk. KDUS has hot cash, potential royalty flow and more. Give us a chunk of that hot-tech company. KDUS is a nicely diversified shell. Biacore is taking Axiom under wing. Lots of cash, almost no burn. Modest license and milestone income almost a certainty. Good shot at royalty income, IMO. Secure patent protection for platform (see next post) from which additional license revenue can (should?) be derived, and additional miscellany. Ex-KDUS scientists and KDUS/OSIP results obviously convinced OSIP management that the core technology was worth licensing. I share your opinion..... they are in the best position to market the platform. Alternatively, if they REALLY love using it, they could turn their non-exclusive into an exclusive with a couple of signatures. Brief translation of the above.... "I haven't a clue". >> To all: May the joy of Christmas be with you and yours. << I'll second that, and throw in a Best of Holidays to all! Rick